Galectin-3 (Gal-3) regulates inflammation and myocardial remodeling and predicts adverse outcomes in myocardial infarction and heart failure, yet its role in catecholamine-driven stress cardiomyopathy, including TS, remains unclear. This evidence concerns the gene LGALS3 and myocardial infarction.